pnc-27 peptide PNC-27, a chimeric p53-penetratin peptide - PNC-27dosage PNC-27, a 32-residue peptide

PNC-27 peptidePrice The PNC-27 peptide is an experimental anti-cancer peptide that has garnered significant attention for its selective cytotoxicity against cancer cells, a key feature that distinguishes it from many traditional cancer therapies.作者：AI Miller·2025—Abstract. The anti-cancer peptide, PNC-27,is cytotoxic to cancer cellsbut has no effect on normal cells and has eradicated tumors in ... Research indicates that PNC-27 operates by targeting the HDM-2 protein, which is often overexpressed on the membranes of cancer cells. This interaction leads to the formation of transmembrane pores, ultimately causing cancer cell lysis, while leaving normal, untransformed cells unharmed. This unique mechanism of action positions PNC-27 as a potential prototype for a new class of cancer-targeting peptides.Anticancer peptide PNC-27 adopts an HDM-2-binding ...

Mechanism of Action: Targeting HDM-2

The primary mechanism by which the PNC-27 peptide exerts its anti-cancer effects involves its interaction with the HDM-2 protein. HDM-2, also known as MDM2, is a protein frequently found on the surface of various solid tissue tumor cells. PNC-27, described as a chimeric p53-penetratin peptide, is designed to bind specifically to this membrane-expressed HDM-2. Upon binding, multiple PNC-27 molecules are thought to associate, facilitating the formation of transmembrane pores. This pore formation disrupts the integrity of the cancer cell membrane, leading to cell death, a process often referred to as membranolysis or necrosisSynergy between Paclitaxel and Anti-Cancer Peptide PNC .... The selectivity of this action is crucial, as studies suggest PNC-27 does not affect normal cells, minimizing the risk of off-target toxicity2016年1月10日—PNC-27 is a tiny and non-toxic part of a protein moleculethat can attach to certain receptor sites only found in cancer cells. PNC-27 causes cancer cells to ....

Preclinical Research and Potential Applications

Preclinical studies have demonstrated the potent anti-cancer activity of PNC-27. In laboratory settings and some in vivo models, PNC-27 has shown the ability to kill cancer cells, eradicate tumors, and reduce tumor growth without apparent harm to healthy tissues. For instance, research has explored its efficacy against cervical cancer cells and its potential in combination therapy, such as with paclitaxel, where it significantly reduced tumor growth in an ovarian cancer model.作者：K Davitt·2014·被引用次数：25—We have developed the anti-cancer peptide,PNC-27, which is a membrane-active peptide that binds to the HDM-2 protein expressed in the cancer cell membranes. The peptide's design as a relatively small, non-toxic molecule further enhances its appeal as a potential therapeutic agentThe anti-cancer peptide,PNC-27, induces tumor cell lysis as the intact peptide. Together they form a unique fingerprint.. Researchers are investigating its application in various cancer types, including multiple myeloma, by targeting the p53 pathway, a critical regulator of cell growth and death.

Regulatory Status and Future Outlook

Despite its promising preclinical results, it is vital to note that the PNC-27 peptide is an experimental compound. Regulatory bodies, such as the U.作者：PM Aguon·2017—PNC-27 is an anti-cancer peptidethat in small in-vitro studies has been shown to induce tumor cell necrosis. It is not currently approved for use in the ...S. Food and Drug Administration (FDA), have explicitly stated that PNC-27 has not been evaluated or approved as a safe and effective treatment for any disease, including cancer. Consumers are cautioned against using any PNC-27 products for medical treatment. The path from preclinical research to an approved therapeutic is long and involves rigorous clinical trials to confirm safety and efficacy in humans.PNC-27, a 32-residue peptidethat contains an HDM-2 binding domain and a cell-penetrating peptide (CPP) leader sequence kills cancer, but not normal, cells by ... Therefore, while PNC-27 represents an exciting development in cancer peptide research, its clinical utility is yet to be established.

The development of the PNC-27 peptide signifies a novel approach to cancer treatment, leveraging targeted molecular interactions to selectively eliminate malignant cells. Its ability to bind to HDM-2 and induce cancer cell lysis without harming normal cells is a key characteristic that drives ongoing researchAnti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique .... However, as an experimental peptide, its future as a viable cancer therapy hinges on successful validation through comprehensive clinical trials and regulatory approval.